Drug Trial Radar · NCT04720313
NXC-201 (Formerly HBI0101) Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jan 1, 2021
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Hadassah Medical OrganizationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nexcella Inc.
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients
Conditions
- Dose Escalation and Safety
Interventions
NXC-201 (formerly HBI0101)Drug
NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of MTDTime frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah University Hospital
Jerusalem, Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.